Whether you’re sorting out the symptoms of an undiagnosed condition or grappling with the weight of a recent diagnosis, gastroparesis can be a complicated and daunting disease to navigate. You’ll ...

Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 ...

Evoke Pharma, Inc. announces its commitment to addressing the needs of patients with gastroparesis following the FDA's update indicating that the supply of unapproved domperidone, used internationally ...

The American Gastroenterological Association (AGA) has released a new clinical guideline with 12 conditional recommendations for diagnosing and managing gastroparesis, a serious and often debilitating ...

Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the USPTO for a patent application covering the use of its GIMOTI® (metoclopramide) nasal spray in patients with moderate ...

Deudomperidone represents a transformative treatment for patients with gastroparesis, for which there is no long-term treatment option currently available.” After readout of the envision3D data, ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global gastroparesis drugs market size is estimated to grow by USD 1.34 billion from 2025-2029, according to ...

The human digestive system is a finely balanced network, yet even minor disruptions can lead to conditions that affect daily life. Gastroparesis and Irritable Bowel Syndrome (IBS) are two such ...

NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024-2028, according ...